Share Name Share Symbol Market Type Share ISIN Share Description
Idmos Plc LSE:IDO London Ordinary Share GB00B035JB54 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 3.00p 0.00p 0.00p - - - 0 05:00:10
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
- - - - 0.72

Idmos (IDO) Latest News

Real-Time news about Idmos (London Stock Exchange): 0 recent articles
More Idmos News
Idmos Takeover Rumours

Idmos (IDO) Share Charts

1 Year Idmos Chart

1 Year Idmos Chart

1 Month Idmos Chart

1 Month Idmos Chart

Intraday Idmos Chart

Intraday Idmos Chart

Idmos (IDO) Discussions and Chat

Idmos Forums and Chat

Date Time Title Posts
11/6/200812:47:::IDMoS:::431
28/2/200815:08IDO Charts and News38
28/8/200518:37IDMoS36

Add a New Thread

Idmos (IDO) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Idmos trades in real-time

Idmos (IDO) Top Chat Posts

DateSubject
27/9/2016
09:20
Idmos Daily Update: Idmos Plc is listed in the sector of the London Stock Exchange with ticker IDO. The last closing price for Idmos was 3p.
Idmos Plc has a 4 week average price of - and a 12 week average price of -.
The 1 year high share price is - while the 1 year low share price is currently -.
There are currently 24,073,212 shares in issue and the average daily traded volume is 0 shares. The market capitalisation of Idmos Plc is £722,196.36.
14/10/2007
12:42
jonwig: Cutting the wage bill, at last! Dental firm fires scientist on eve of launch DOUGLAS FRIEDLI IDMOS, the Aim-listed dental technology company which recently fired its chief executive, has ousted another senior figure on the eve of a key product launch. Research director Przemyslaw Los, who played a key part in developing Idmos's tooth decay detection system, has been made redundant amid rumours of a rift within the Dundee University spin-out. Los was Idmos's most senior non-board member and had held the key research role for four years after holding academic posts at universities including California, St Andrews, Dundee and Wroclaw in Poland. A spokeswoman for Idmos said Los was working out his notice after the company had shifted its focus away from research. His departure follows Idmos chairman John Pool's sacking of chief executive Steven Westwood in July. Pool claimed Westwood, who saw Idmos through flotation, had "run out of technical knowledge". As a result of the departures, Idmos will be without two of its key figures as it prepares for this week's launch of its Caries Management Support System and Caries Detection Device at the British Dental Trade Association conference in Birmingham. When Idmos floated in 2004, it said it would launch the Caries Management Support System by the end of 2006. Shares in the company plunged by 66% in a year as the launch was delayed. They rose again after the company revealed that its disease detection device would be recommended by Denplan, the UK's largest dental plan provider, to its network of 6,500 dental practices. The share price closed on Friday at 44p. The deal with Denplan is a departure for Idmos, which previously worked closely with a US-based distributor Dentsply. Reports this summer suggested that Dentsply was dragging its heels over the approval of Idmos devices. Idmos' spokeswoman said Dentsply retained distribution rights outside the UK and Ireland. An employment tribunal action against Idmos brought by former senior administrator Lorna Clark, which was due to be heard this week, has been postponed. The company is now run on a day-to-day basis by chief operating officer Graham Lay, a former Johnson & Johnson executive. The firm's main product is a sound-wave probe which can detect the onset of tooth decay. The same technology could be used to detect diseases in other areas, such as bones. Idmos was set up to commercialise dental technology developed at St Andrews and Dundee universities. Westwood joined in 2004 and helped to steer the company through a flotation that year which raised £5m and a further £2m this year. http://business.scotsman.com/technology.cfm?id=1639732007
16/7/2007
20:13
amberandorange: Interesting responses from the Chairman but I find it difficult to believe that any of this was news to the Board, they would have seen the burn rate,known about the problems with the launch and sanctioned the expenditure for widening opportunities for further exploitation of the technology ( much too soon in my view). The company must deliver what it set out to do. I can see no reason for spending any money on anything not to do with the launch of the dental products. AS I have stated before the Board must be reorganized and strengthened with commercial operational expertise. At present there are too many directors Directors should be compensated on a performance based process.The headcount needs to be reviewed to deliver short term results and get the share price up
15/7/2007
15:47
jonwig: Lifting the lid a bit here, but still a lot unanswered: Sacked Idmos chief 'ran out of knowledge' DOUGLAS FRIEDLI STEPHEN Westwood, the ousted chief executive of dental technology company Idmos, was removed because he "ran out of technical knowledge", chairman John Pool has claimed. Westwood was sacked last week amid claims that investors were furious about a two-thirds decline in the company's share price and delays to the launch of its lead product. But Pool, who has ordered a review of Idmos's operations, said Westwood left because he had taken the company as far as he could go: "He just ran out of technical knowledge. He got out of his technical background. He was starting to feel uncomfortable with where he was. "Anyone who has been in life sciences knows there are phases of a company where you have an input, and then you need a different input, and we were getting to the phase where we needed a different input." Westwood did not return calls from Scotland on Sunday. Westwood's job is likely to be taken by Graham Lay, the company's operations director who is expected to become chief operating officer this week. Pool said: "Graham Lay is a guy who we have looked for for some considerable length of time. He is far more aggressive than Stephen was. You can be aggressive if you have the technical knowledge. He is probably the strongest candidate for chief executive. I have no doubt about that." Scotland on Sunday last week revealed that Lay had been appointed operations director, and subsequent events have turned the spotlight on the former Johnson & Johnson executive. Pool said he had ordered a review of the Dundee company's business to cut costs and speed up the development of a new range of medical devices which use its sound wave technology in bones and other tissue. Among the measures being considered are a reduction in pay for some directors and more efficient manufacturing processes at its suppliers. He added that Idmos had considered moving manufacturing to Dentsply, the US group which is expected to distribute its products. Idmos's main product is a sound wave probe which can detect the onset of tooth decay. The same technology could be used to detect osteoporosis, and Pool said he hoped to have such a device on the market by the middle of next year. He said: "Even if we get 100% of the dentists' sales, it will still be less than the potential on the medical side." Pool last week switched from a non-executive to an executive role to guide Idmos through his proposed changes. He said he was disappointed by Idmos's share price, which collapsed this year when the company raised money to get its first products to market: "I don't think it represents the potential there is in the company. It is the way of the Alternative Investment Market at the moment; I am involved with another company which has £30m worth of contracts yet its value is just £17m." Pool said Westwood had been "a gentleman" in agreeing to help in the handover of the company to Lay and the board, including chief clinical officer Nigel Pitts, technology director Chris Longbottom and corporate development director Francis Madden. Idmos was set up to commercialise dental technology developed at St Andrews and Dundee universities. Westwood joined in 2004 and helped to steer the company through a flotation that year which raised £5m and a further £2m this year. http://scotlandonsunday.scotsman.com/business.cfm?id=1101282007
07/6/2007
22:17
cragside: Any reason why the share price has not dropped to 35p yet? Maybe tomorrow
23/4/2006
08:53
jonwig: A leak to the Sunday Press: IDMoS names industry veteran to head worldwide sales drive DOUGLAS FRIEDLI IDMOS, the dentists' lab technology company, will this week reveal it has recruited an industry veteran to spearhead a move towards generating sales. Andrew Greaves will join the Dundee company as commercial manager in charge of its dental business. He was previously export sales manager of Oxford Immunotech, an Oxford University spin-out company which developed technology to diagnose tuberculosis. Greaves will take over a number of roles which had been handled by Stephen Westwood, chief executive of IDMoS. In particular, he will manage the company's relationship with Dentsply, the US dental equipment distributor, and manage logistics and after-sales service. Dentsply's chief executive, Gary Kunkle, told US analysts recently about IDMoS's Caries Management and Support device. He said: "We really expect and hope that we can get that out in the late 2006." Under the deal, Dentsply will sell IDMoS equipment in some of the 120 markets which it supplies worldwide and provide help on product development and regulatory approval. The company plans to make further senior appointments, including a project manager for its development programme. It is also looking to create a scientific advisory board to build on the technical expertise which it draws from chief clinical officer Nigel Pitts, a Dundee University professor. IDMoS, which is traded on the Alternative Investment Market, will present its results for the six months to January on Tuesday, when it is expected to reveal that it has made progress with technology which will provide dentists with a three-dimensional image of a tooth. The 3D system is expected to go on sale within the next two or three years. The company's CMS gadget passes electrical current through teeth to identify decay. This provides more accurate data than x-rays without the side effects. The same technology may one day be used to detect cancerous cells in the rest of the body. IDMoS is still at an early stage and there is no chance it will report a profit on Tuesday. It made a loss of £2.1m in the year to July 2005, up from £750,000 the previous year. http://business.scotsman.com/technology.cfm?id=607882006 Of course, they are building up high expectations for sales starting this year. Any slippage will impact the share price - maybe it would have been better to under-promise??
26/4/2005
15:57
trader2: News may be good but the chart looks dire. Share price only knows how to go south!
Idmos share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20160927 12:10:22